Beijing, China

Qiuwen Wang

This inventor holds 1 USPTO granted patent and 9 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignee: Beone Medicines I Gmbh. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Qiuwen Wang. Retrieved from https://idiyas.com/inventor/qiuwen-wang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Qiuwen Wang

Introduction

Qiuwen Wang is an accomplished inventor based in Beijing, China. He is affiliated with Tsinghua University, where he contributes to the field of research and innovation. Although he currently holds no granted patents, his work is focused on significant advancements in pharmaceutical compositions and treatments.

Latest Patent Applications

Qiuwen Wang's latest patent applications include KAT6 Inhibitors. These applications disclose compounds used as inhibitors of KAT6 and pharmaceutical compositions comprising these compounds. The methods outlined aim to treat disorders or diseases responsive to the inhibition of KAT6 activity in a subject. The compounds are described in detail, including various forms such as pharmaceutically acceptable salts, deuterated analogs, N-oxides, and tautomers.

Conclusion

Qiuwen Wang's contributions to the field of innovation, particularly in the area of KAT6 inhibitors, highlight his commitment to advancing medical science. His ongoing research at Tsinghua University promises to lead to significant developments in the treatment of various disorders.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…